This guide sorts pain by mechanism (nociceptive, neuropathic, nociplastic) and matches tools to each. The best-documented agent here is topical DMSO, a transdermal carrier with anti-inflammatory properties: one controlled trial supports it in complex regional pain syndrome, and it is FDA-approved for interstitial cystitis. Other options range from moderate-evidence topical NSAIDs to preclinical peptides. The framework's claim that root-cause treatment beats symptom suppression is a position, not a tested outcome.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does DMSO work for pain?
It has one controlled trial supporting topical DMSO for CRPS I with rare side effects, and FDA approval for interstitial cystitis by intravesical instillation. Its role as a transdermal carrier is well documented; other pain uses are off-label with limited trial data.12
What is the difference between pain types?
Nociceptive pain comes from tissue damage and inflammation; neuropathic from nerve injury; nociplastic from a sensitized nervous system amplifying signals. Each needs a different approach: anti-inflammatory and regenerative for the first, nervous-system downregulation for the last.
Is DMSO safe on skin?
Reasonably, with conditions: it needs pharmaceutical-grade, diluted material on clean skin because it carries surface contaminants inward, and a harmless garlic-like odor is expected. The entry cautions against it in pregnancy, asthma and significant liver or kidney dysfunction; IV use belongs in clinical settings.
Do peptides help with pain?
Indirectly, in theory: BPC-157 and TB-500 target tissue healing rather than pain signaling, and their evidence is strong preclinical but thin in humans. Khavinson bioregulators come from Soviet clinical tradition with few Western trials.
What would change this rating?
Controlled trials of the integrative approach itself, plus human randomized trials for the peptide agents. Today the strongest evidence is for conventional topicals and one DMSO-in-CRPS trial.1
Integrative pain management in the Heretic framework prioritizes addressing root causes of pain rather than symptom suppression. This file covers DMSO therapy as a transdermal carrier and anti-inflammatory agent, topical analgesic protocols, and the intersection of pain with broader biohacking approaches including peptide therapy, regenerative medicine, and nervous system modulation.
02Overview
Pain is a bioplastic signal — it reflects the state of the nervous system, inflammatory milieu, and tissue integrity. Effective pain management requires distinguishing between:
| Pain Type | Mechanism | Primary Treatment Approach |
|---|---|---|
| Nociceptive | Tissue damage/inflammation | Anti-inflammatory, regenerative |
| Neuropathic | Nerve damage/dysfunction | Nervous system modulation, peptides |
| Nociplastic | Sensitized nervous system | DOWNREGULATION, lifestyle, peptides |
| Mixed | Multiple mechanisms | Multi-modal approach |
Swipe table →
The conventional approach — NSAIDs, opioids, corticosteroids — primarily suppresses the signal without addressing the cause. The integrative approach asks: why does this tissue generate pain, and what can we do about the underlying pathophysiology?
03DMSO (Dimethyl Sulfoxide)
What is DMSO?
DMSO is a sulfur-based organic compound (CH₃SOCH₃) that has been used clinically since the 1960s. Its primary clinically useful property is penetration enhancement — it rapidly penetrates skin and membranes, carrying other compounds with it. It also has independent anti-inflammatory, analgesic, and antioxidant properties.
Mechanisms of Action
| Mechanism | Evidence | Clinical Relevance |
|---|---|---|
| Transdermal carrier | Well-established | Enables delivery of NSAIDs, herbs, analgesics through skin |
| Membrane fluidity modification | Basic science | May improve cellular repair signaling |
| Anti-inflammatory (via NF-κB inhibition) | Moderate | Comparable to some NSAIDs in topical form |
| Antioxidant (scavenges hydroxyl radicals) | In vitro | May reduce oxidative damage in injured tissues |
| Vasodilation | Observed clinically | Improves local blood flow |
| Collagen modulation | Preliminary | May support connective tissue repair |
Swipe table →
FDA-Approved and Off-Label Uses
| Use | Status | Formulation |
|---|---|---|
| Interstitial cystitis | FDA-approved ( symptomatic relief) | 50% DMSO intravesical instillation |
| Amyloidosis | FDA-approved (rare) | DMSO IV |
| Topical analgesia | Off-label | 40-90% topical DMSO |
| Scar tissue / fibrosis | Off-label | Topical DMSO + compounds |
| CRPS (Complex Regional Pain Syndrome) | Off-label, evidence-based | Topical DMSO 50% |
| Plantar fasciitis | Off-label | Topical DMSO + NSAIDs |
Swipe table →
Evidence for Specific Applications
CRPS (Complex Regional Pain Syndrome)
A controlled trial ( PMID 22266201) found that topical DMSO 50% was effective for CRPS I, with side effects being rare and overall relief significant. CRPS represents one of the strongest evidence-based uses for topical DMSO.
As a Penetration Enhancer
DMSO's ability to enhance transdermal drug delivery is well-documented ( PMID 22030943). It works by: - Disrupting stratum corneum lipid structure - Increasing partition coefficient for drugs - Enabling delivery of both lipophilic and hydrophilic compounds
Neuropathic Pain
Early clinical evidence suggests topical DMSO may help with neuropathic pain, though robust RCT data is limited.
Uses
DMSO Compound Combinations
DMSO can carry multiple compounds transdermally. Common combinations:
| Combination | Concentration in DMSO Solution | Purpose |
|---|---|---|
| DMSO + Ibuprofen | 10-20% ibuprofen gel dissolved in DMSO | Anti-inflammatory + carrier |
| DMSO + Magnesium | 10% magnesium chloride hexahydrate | Muscle relaxation, nerve stabilization |
| DMSO + Methylsulfonylmethane (MSM) | 10% MSM | Sulfur donor, anti-inflammatory |
| DMSO + Lidocaine | 2-5% lidocaine | Acute pain relief |
| DMSO + Vitamin B12 | Cyanocobalamin solution | Nerve health (theoretical) |
| DMSO + Corticosteroid | 1% hydrocortisone | Potent anti-inflammatory (short-term use only) |
Swipe table →
DMSO for Systemic Administration (IV/Intraperitoneal)
- IV DMSO is used in some integrative oncology and autoimmune protocols
- Requires medical supervision; typically 10-50% solution
- Significant risk if impurities present — pharmaceutical-grade DMSO only
- Not recommended outside of clinical settings
DMSO Quality and Handling
| Concern | Recommendation |
|---|---|
| Purity | Use only USP/pharmaceutical grade DMSO (99.9%+ purity) |
| Dilution | Always dilute before topical use — never apply full-strength |
| Solvents | Use distilled or sterile water for dilution |
| Storage | Keep sealed, dark, room temperature; DMSO absorbs containers |
| Contamination | Use glass or HDPE plastic; avoid PVC (leaches plasticizers) |
| Body odor | DMSO metabolizes to dimethyl sulfide (DMS) — causes garlic-like body odor; harmless |
| Herxheimer reactions | In some cases, initial worsening of symptoms due to microbial die-off |
Swipe table →
Contraindications and Cautions
| Contraindication | Reason |
|---|---|
| Pregnancy | Not established as safe |
| Asthma | Inhaled DMSO vapor may irritate airways |
| Cardiac conduction abnormalities | IV DMSO may affect cardiac rhythm (theoretical) |
| Liver/kidney dysfunction | Impaired DMSO metabolism |
| Concurrent grapefruit juice | Theoretical interaction concerns |
Swipe table →
Common Side Effects
| Side Effect | Frequency | Management |
|---|---|---|
| Garlic-like body odor | Very common | Manageable; DMS byproduct |
| Skin irritation/rash | Occasional | Dilute further; reduce frequency |
| GI upset | Rare (oral/IV) | Not used orally |
| Photosensitivity | Rare | Avoid sun exposure on treated area |
| Headache | Rare | Usually resolves with dose reduction |
Swipe table →
04Uses
Conventional Topical NSAIDs
| Compound | Formulation | Indication | Evidence |
|---|---|---|---|
| Diclofenac gel 1% | Voltaren Gel | Osteoarthritis, musculoskeletal | RCTs — moderate evidence |
| Ketoprofen gel | Compounded 10-20% | Tendinopathy, arthritis | Moderate evidence |
| Indomethacin gel | Various | Inflammation, joint pain | Moderate evidence |
| Capsaicin | 0.025-0.075% | Neuropathic, arthritic | Good evidence for neuropathic |
| Lidocaine 5% | Patch or gel | Neuropathic, localized | Good for post-herpetic neuralgia |
Swipe table →
Natural Topical Analgesics
| Agent | Mechanism | Concentration | Evidence |
|---|---|---|---|
| Arnica montana | Anti-inflammatory (helenalin) | 10-20% gel/cream | Mixed; widely used for trauma |
| Boswellia (Frankincense) | 5-lipoxygenase inhibition | 5-15% cream | Moderate for osteoarthritis |
| Ginger extract | Anti-inflammatory, warming | 5-10% | Preliminary |
| Turmeric/Curcumin | NF-κB inhibition | 3-10% | Preliminary |
| MSM | Sulfur donor, anti-inflammatory | 10% | Theoretical |
| Menthol | TRPM8 activation → cooling sensation | 1-5% | Symptomatic relief |
| Camphor | TRPV3 activation → warming | 1-10% | Symptomatic relief |
Swipe table →
Cannabinoid Topicals (Where Legal)
| Agent | Mechanism | Application | Evidence |
|---|---|---|---|
| CBD (cannabidiol) | CB2 activation, TRPV1 | 2-10% cream/gel | Growing evidence for chronic pain |
| THC | CB1/CB2 | 1-5% (not psychoactive transdermally) | Preliminary |
| Full-spectrum | Entourage effect | 5-10% | Anecdotal > evidence |
Swipe table →
05Peptide-Based Pain Management
Several peptides have demonstrated analgesic or healing-promoting properties relevant to pain management:
BPC-157 (Body Protection Compound)
Primary relevance: Healing of GI tract, tendons, ligaments, and nerves — addressing root causes of pain rather than symptom suppression.
| Property | Detail |
|---|---|
| Mechanism | Upregulates growth hormone receptors, promotes angiogenesis, stabilizes cell membranes |
| Pain application | Tendinopathy, joint pain, nerve injury, post-surgical |
| Dosing | — |
| Evidence | Strong preclinical; limited human RCTs |
| PMID | See BPC-157 (Body Protection Compound) |
Swipe table →
TB-500 (Thymosin Beta-4)
| Property | Detail |
|---|---|
| Mechanism | Promotes cell migration, reduces inflammation, supports tissue repair |
| Pain application | Muscle injuries, wound healing, anti-inflammatory |
| Dosing | — |
| Evidence | Preclinical strong; human data limited |
| PMID | See TB-500 (Thymosin Beta-4) |
Swipe table →
Khavinson Peptides (Russian Bioregulators)
| Property | Detail |
|---|---|
| Relevance | May support tissue regeneration and nervous system function |
| Notable | Cortexin (brain/pain), retinalamins (eye), thymulin (immune) |
| Evidence | Soviet clinical tradition; limited Western RCTs |
| PMID | See Khavinson Peptides (Russian Bioregulators) |
Swipe table →
06Uses
Uses
| Phase | Intervention |
|---|---|
| 0-20 min | Rest, protect, control swelling |
| 20 min-72 hrs | — |
| Anti-inflammatory | — |
| Peptide support | — |
| After acute | Begin gentle loading and physical therapy |
| For pain | Topical DMSO + ibuprofen as needed |
Swipe table →
Uses
| Agent | Mechanism |
|---|---|
| Alpha-lipoic acid | Oxidative stress reduction, nerve conduction |
| Acetyl-L-carnitine | Nerve mitochondrial function |
| Benfotiamine | Thiamine pyrophosphate; nerve energy |
| Magnesium | NMDA modulation |
| Topical DMSO + lidocaine | Local nerve stabilization |
| BPC-157 | Nerve healing (theoretical) |
Swipe table →
07Pain and the Nervous System
Central Sensitization
Chronic pain often involves wind-up and central sensitization — the CNS amplifies pain signals beyond the peripheral input. Addressing this requires:
| Approach | Mechanism |
|---|---|
| Vagus nerve stimulation | Activates descending inhibitory pathways |
| Breathwork / coherent breathing | Reduces sympathetic tone |
| Cold exposure | Norepinephrine release → pain inhibition |
| Sleep restoration | CNS glymphatic clearance |
| Ketamine (low-dose) | NMDA antagonism |
| Psilocybin (clinical trials) | Neuroplasticity, default mode network reset |
Swipe table →
Pain and the Polyvagal Connection
Stephen Porges' Polyvagal Theory suggests that the ventral vagal state is incompatible with chronic pain states — engaging social engagement and safety physiology may directly reduce pain sensitivity. See Polyvagal Theory.
08Notes
- NSAIDs: Useful short-term for acute inflammation but carry GI, cardiovascular, and renal risks with chronic use; topical forms reduce systemic exposure
- Opioids: Outside appropriate acute/post-surgical contexts, chronic opioid therapy for non-cancer pain is generally counterproductive and harmful
- Steroid injections: Provide temporary relief but may impair tendon/ligament integrity with repeated use
- DMSO quality is critical: Industrial DMSO contains impurities that can be carried transdermally — use only pharmaceutical-grade
- The pain-immune connection: Chronic pain and immune activation are intertwined; addressing systemic inflammation often reduces pain
09Practical Context
When to Use DMSO
| Situation | DMSO Useful? |
|---|---|
| Acute musculoskeletal injury | Yes — early anti-inflammatory effect |
| Chronic joint pain (osteoarthritis) | Yes — disease modification potential |
| Neuropathic pain | Moderate — as adjunct |
| CRPS | Yes — relatively strong evidence |
| Tendinopathy | Yes — penetrates deep tissue |
| Post-herpetic neuralgia | Moderate — as adjunct |
| Headache (tension-type) | Possibly — topical to neck/temples |
| Acute migraine | Not recommended |
Swipe table →
Storage and Handling
- DMSO crystallizes at low temperatures (18°C/65°F) — warm to dissolve before use
- Use glass droppers or HDPE plastic — never PVC
- DMSO will dissolve plastic and leach chemicals from unsuitable containers
- Apply to clean skin only — carries anything on the skin surface into the body
10Connections
11Sources
- PubMed 22266201PubMed 22266201
- PubMed 22030943PubMed 22030943
12Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.